Quoin Pharmaceuticals
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 4
- Market Cap
- $2.4M
- Introduction
Quoin Pharmaceuticals Ltd. engages in the development of therapeutic products for the treatment of rare and orphan diseases. Its product pipeline includes QRX003, QRX004, QRX007, and QRX008. The company was founded by Michael Myers and Denise Carter on March 5, 2018 and is headquartered in Ashburn, VA.
Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Quoin Pharmaceuticals
- Target Recruit Count
- 20
- Registration Number
- NCT05789056
- Locations
- ๐บ๐ธ
Site #1, San Diego, California, United States
๐บ๐ธSite #4, Indianapolis, Indiana, United States
๐บ๐ธSite #2, San Antonio, Texas, United States
Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Quoin Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT05521438
- Locations
- ๐บ๐ธ
Site #1, San Diego, California, United States
๐บ๐ธSite #4, Indianapolis, Indiana, United States
๐บ๐ธSite #3, Charleston, South Carolina, United States
ยฉ Copyright 2024. All Rights Reserved by MedPath